NCT05866679暂停1 期
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03
研究概览
简要总结
To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.
详细描述
Primary Objective:
- To assess if increased lactate production measured by HP 13C MRI occurs in suspected ovarian cancer patients who will undergo surgery
- To evaluate the proportion of increased lactate production in the ovaries measured by HP 13C MRI in low/high ovarian cancer risk patients.
Secondary Objectives:
- Correlate HP-MR findings to metabolomics, immune profiles, and blood biomarkers of patients undergoing surgical resection.
- Demonstrate the feasibility and utility of metabolic imaging with HP 13C pyruvate MR in patients with suspected ovarian cancer
- Correlating imaging findings such as enhancement pattern, ADC values, and advanced image analytics such as texture with pathology and genetic analysis for patients who will undergo surgical resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Months 至 —（Child, Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •For the first cohort, the following selection criteria will be applied who are undergoing a screening exam at MD Anderson:
- •Patients with a first degree relative (mother, sister, or daughter) with ovarian cancer or
- •A personal history of breast cancer before age 40 or
- •A personal history of breast cancer diagnosed before age 50, and one or more close relatives diagnosed with breast or ovarian cancer at any age. Two or more close relatives diagnosed with breast cancer before age 50 or with ovarian cancer diagnosed at any age or
- •Ashkenazi Jewish heritage and a personal history of breast cancer before age 50 or
- •Ashkenazi Jewish heritage and a first- or second-degree relative diagnosed with breast cancer before age 50 or with ovarian cancer at any age or
- •Presence of a BRCA1 or BRCA2 mutation or
- •Presence of a mismatch repair gene mutation associated with a hereditary cancer syndrome known as Hereditary Non-Polyposis Colon Cancer (HNPCC)/Lynch syndrome. For the second cohort- 10 Patients will be enrolled who present to MD Anderson for a pelvic ultrasound or have an outside ultrasound or imaging study without a mass or have an adnexal mass (benign) on outside imaging and do not have a high risk for ovarian cancer.
- •For the third cohort of patients:
- •10 patients who have suspicion of ovarian malignancy on conventional imaging and will be undergoing surgical resection will be included.
排除标准
- •(all cohorts)
- •1. Children, pregnant women, cognitively impaired adults, or prisoners will be excluded from participation.
研究组 & 干预措施
Hyperpolarized 13-C-pyruvate
Experimental
干预措施: Hyperpolarized 13-C-pyruvate (Drug)
结局指标
主要结局
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03
时间窗: through study completion: an average of 5 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
MRI in Staging Ovarian Cancer Using MRI Contrast AgentOvarian CancerNCT00463996University of Aarhus50
终止
1 期
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerAdvanced Solid Tumors (Excluding Prostate Cancer)Ovarian CancerNCT04267939Bayer14
已完成
不适用
Early evaluation of tumor response using contrast-enhanced ultrasonography for hepatocellular carcinoma treated with Solafenibhepatocellular carcinomaJPRN-UMIN000004599Yokohama City University Medical Center Gastroenterological Center80
已完成
早期 1 期
IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOCOvarian CancerNCT03378297Haukeland University Hospital26
撤回
不适用
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer ExamProstate AdenocarcinomaNCT04286386M.D. Anderson Cancer Center130